Point mutations in the X-linked ornithine transcarbamylase (OTC) gene have been detected at the same Taq I restriction site in 3 of 24 unrelated probands with OTC deficiency. A de novo mutation could be traced in all three families to an individual in a prior generation, confirming independent recurrence. The DNA sequence in the region of the altered Taq I site was determined in the three probands. In two unrelated male probands with neonatal onset of severe OTC deficiency, a guanine (G) to adenine (A) mutation on the sense strand (antisense cytosine ICI to thymine [I1) was found, resulting in glutamine for arginine at amino acid 109 of the mature polypeptide. In the third case, where the proband was a symptomatic female, C to T (sense strand) transition converted residue 109 to a premature stop. These results support the observation that Taq I restriction sites, which contain an internal CG, are particularly susceptible to C to T transition mutation due to deamination of a methylated C in either the sense or antisense strand. The OTC gene seems especially sensitive to C to T transition mutation at arginine codon 109 because either a nonsense mutation or an extremely deleterious missense mutation will result.
Introduction
Ornithine transcarbamylase (OTC)' (E.C. 2.1.3.3) is the Xlinked hepatic enzyme that catalyzes the intra-mitochondrial condensation of ornithine and carbamylphosphate in the second step ofthe urea cycle. Males with classical OTC deficiency (McKusick 31125) experience neonatal ammonia intoxication with severe or fatal neurological damage (1) . Female carriers may be asymptomatic, but often experience some degree of protein intolerance. They, as well as males with partial enzymatic deficiencies, may have a normal lifespan but are at risk 1 . Abbreviations used in this paper: A, adenine; C, cytosine; G, guanine; OTC, ornithine transcarbamylase; RFLP, restriction fragment length polymorphism; T, thymine.
for stress-induced hyperammonemic crises and incremental neurological damage (1) .
OTC activity is usually undetectable in liver tissue from severely deficient males, although OTC-specific mRNA and/ or the protein product may be present (2, 3) . Males with partial OTC activity may have diminished enzyme levels, or normalto-high levels with abnormal kinetic properties (2) . In DNA studies, a few cases of severe deficiency have been shown to be caused by deletion ofpart or all ofthe OTC gene (4-7), and we have seen one male with a mild deficiency due to mosaicism for a deletion within this gene (Maddalena, A., and R. L. Nussbaum, manuscript in preparation). Biochemical studies (2, 3) and mouse models (8, 9) suggest that a variety of different point mutations may be responsible for heterogeneity in OTC deficiency. As a consequence, family studies are usually accomplished with restriction fragment length polymorphisms (RFLP) rather than by direct detection of the mutation (4, 10-12; Nussbaum, R. L., unpublished observations).
The detection of a point mutation by a restriction enzyme depends on the unlikely coincidence that the mutation creates a new recognition site or eliminates an existing one. However, restriction sites containing the sequence cytosine (C):guanine (G) appear to have an intrinsically higher mutation risk (13) . The relatively rare CG dinucleotide is the major site ofmethylation in human DNA; once methylated, the C in either strand may be mutated to a thymidine by spontaneous deamination. Accordingly, we routinely screen DNA from OTC patients using the enzyme Taq I (recognition sequence TCGA), in addition to using Msp I (CCGG) for RFLP studies. Abnormal Taq I restriction fragments have been detected in 4 of 24 unrelated families analyzed. In three of these unrelated families, an alteration of the same Taq I site was seen, resulting in the loss of the usual Taq I fragment of 1.8 kb and the appearance of a new 3.4-kb fragment. The fact that these mutations occurred independently in three families suggested that this particular Taq I site in the OTC gene was prone to mutation. We have now localized this Taq I site within the OTC gene, determined its DNA sequence, and identified two different C:G to thymine (T):adenine (A) transition mutations responsible for the severe OTC deficiency in these three families.
Methods
OTCcDNA probes. pHOCl (14) contains a 1.2-kb OTC cDNA, which is lacking -0.4 kb of5' exonic sequence. pHOCl detects genomic Taq I restriction fragments of 4.6, 3.8, 2.7, 1.9 (faint), 1.8, and 1.4 kb.
pHOC3 contains a filfl-length OTC 1.5-kb cDNA insert originally isolated from a human liver cDNA Xgtl 1 library by hybridization with pHOCl (A. Maddalena and R. L. Nussbaum). The insert encodes functional OTC enzyme when inserted in an expression vector and transfected into cultured cells (Nussbaum, R. L., unpublished observations). Additional Taq I genomic fragments detected by pHOC3 are 0.9 and 0.8 kb, and a second fragment of 4.6 kb. Oligonucleotide hybridization. Oligonucleotide hybridization was performed on nitrocellulose blots. Hybridization and washing followed the tetramethylammonium chloride procedure (17) as described by DiLella and Woo (18) , except that probe concentration was 105-106 cpm/ml. A washing temperature of 54°C (3-4°below the dissociation temperature for an 1 8-mer) was used.
Case histories. Families Bo and En have been described (previously designated families A and B) (14) . The probands in both were severely OTC-deficient male infants whose partially deficient mothers were diagnosed after the birth of the affected child. The proband of family Bo was originally reported as severely neurologically damaged; he died at the age of 2½/2 yr, having achieved no growth or developmental milestones since infancy. The proband in family En died during the first week of life. Southern blots of the OTC genes of both infants showed the absence ofa normal 1.8-kb Taq I fragment and the appearance ofan abnormal 3.4-kb fragment. Their mothers and other maternal relatives with demonstrable protein intolerance also had the 3.4-kb marker. In both families, a generation was available for testing in which neither the 3.4-kb fragment nor protein intolerance were found.
The proband in family Ma is a 21-yr-old female who had sporadic episodes of neurological dysfunction with symptoms including severe headaches, behavioral changes, and loss of consciousness. After an episode at age 12, she was diagnosed as partially OTC deficient on the basis of hyperammonemia (257 nm/liter) and orotic aciduria (8, 266 ,g/mg creatinine) following a meal of 0.75 g protein/kg body wt. She presently avoids high protein foods voluntarily but is somewhat noncompliant in taking her prescribed sodium benzoate and calcium gluconate. Since diagnosis, she has required occasional hospitalization for mild to moderate hyperammonemia. She has completed high school but is recognized as intellectually slow. Partial OTC deficiency was also diagnosed by protein-loading studies in her mother, who has an aversion to proteins, and one sister, who is asymptomatic. Another sister and the maternal grandmother have normal protein tolerance. There are no male siblings, and no male neonatal deaths in the extended family.
Results
Southern blot analysis. Southern blots of the OTC gene in family Ma showed normal restriction patterns with every enzyme tested except Taq I (J. E. Spence and W. E. O'Brien). The three females with confirmed OTC deficiency had an aberrant fragment at 3.4 kb, in addition to the normal Taq I fragments (Fig. 1) . The same aberrant fragment at 3.4 kb was seen in the OTC heterozygotes and hemizygotes in the Bo and En families (14) . The 3.4-kb marker appeared nowhere else in the family. As with families Bo and En, it is possible to pinpoint a generation in the Ma family in which the metabolic deficiency and the 3.4-kb marker jointly appeared: individual I.1 has both traits, while her mother (I.2) has neither. Barring low-level somatic or germline mosaicism, her father (I. 1), who was not available for study, is excluded from having OTC deficiency by history, and from carrying the 3.4-kb marker by the normal Southern blot of a second daughter (data not shown). The 18-kb insert of JB1 was subcloned and partially sequenced as shown in Fig. 2 . It contained sequences from the central to 3' region ofthe OTC gene, as shown by hybridization with cDNA fragments (Maddalena, A., and R. L. Nussbaum, data not shown). The XJB1 insert was subcloned into pUC19 as a series of Pst I fragments. The exon-containing Pst I subclones were identified, and their linear order was confirmed, by hybridization with OTC cDNA fragments. A plasmid containing the region of the mutation, pJB 19, was detected with probe pHOC 1-A. Its 1.7-kb insert was subcloned into M 13 and sequenced in both directions from an internal Rsa I site as indicated.
II
Genomic sequence ofproband Bo. The genomic sequence from proband Bo corresponded with two exceptions to a central portion ofthe published cDNA sequence, defining an exon of 154 bases (Fig. 2) . Flanking the exon are introns with standard splice signals. Of the two alterations found in the sense sequence, one is a silent T to G transversion in the third position of the codon for Leu 19. The other is a G to A transition that changes codon 109 from CGA (arginine) to CAA (glutamine). Together with the preceding T, the normal CGA codon constitutes a Taq I site, which a G to A transition would destroy. In addition to changing the Southern blot pattern for Taq I, this mutation causes an amino acid substitution that could have a significant effect on protein stability or function. Also, the inability ofcDNA probes to detect a normal genomic Taq I fragment of 1.6 kb in Southern blots of normal individuals is now easily explained by the fact that there are only 34 bases of exonic sequence 5' to this Taq I site.
Detection of the mutations in families En and Ma with oligonucleotide probes. The genomic sequence was then used to produce a series of synthetic oligonucleotide probes for direct analysis of the mutation site in families En and Ma. The normal, or arginine specific, probe had the sequence TATTGGCTCGAGTGTATA, with the Taq I site centrally located (underlined). The probe corresponding to the glutamine missense mutation contained A instead of G at position 10. A third probe had the other likely substitution, a C to T transition at position 9, which in this reading frame would create a stop (UGA) mutation.
This set of probes was hybridized to Southern blots of Pst I digested DNA and washed under conditions requiring a perfect match (18, 19 Autoradiographs from these experiments are shown in Fig.  3 . Four identical blots were prepared from Pst I digests of the male proband of family Bo (lane 1), a normal male control (lane 2), the carrier mother of family En (lane 3), and the female proband of family Ma (lane 4). In panel a the complete hybridization pattern of the full length cDNA is shown, including the 1.7-kb fragment which is present in all samples (arrow). The greater intensity in the female samples corresponds to the dosage ofX chromosomes. In panel b, the probe was the arginine-specific oligonucleotide corresponding to the normal sequence. Signals of equal intensity are seen at 1.7 kb from the male control and the two heterozygous females, but not the family Bo proband. In panel c, the probe corresponding to the glutamine substitution in proband Bo hybridizes with his DNA in lane 1 but not with the control in lane 2, as expected. In lane 3, hybridization with this probe indicates that the mutation found in family Bo is also present in family En. Proband Ma did not share this sequence, but in panel d, lane 4, her mutation was found to be the premature stop codon resulting from a C:G to T:A transition.
Discussion
Recurrent mutations at CG dinucleotides. Three unrelated individuals with OTC deficiency who shared an anomalous Taq I restriction fragment do in fact have point mutations in the same Taq I site within an exon of the OTC gene. All three mutations are ofthe type proposed to occur at methylcytosines in CG dinucleotides. Given the reading frame T CGA, direct C to T transition in the sense strand would create the stop codon; C to T transition in the antisense strand would, upon replication, lead to the G to A missense substitution. In all three instances, this X-linked mutation first appeared in the somatic tissues ofa female and thus could have occurred in either male or female gametogenesis. It may be possible to trace the parental origin of these mutations by means of RFLP analysis of appropriate family members.
Structural impact ofthe mutations. The nonsense mutation was observed in a symptomatic female, who evidently had insufficient numbers of hepatic cells with the normal OTC gene active to prevent protein intolerance and hyperammonemia. The polypeptide produced from this allele would be truncated at less than half its normal length and completely lack the carboxyterminal residues proposed to be involved in ornithine binding (20) . We have not observed this mutation in the hemizygous state, but we expect that it would confer complete OTC deficiency.
The missense substitution of glutamine for arginine 109 was observed in two male neonates. No OTC activity was measurable in a post-mortem liver sample from proband En. Although enzyme assay was not performed in proband Bo, he had a similar clinical and biochemical picture to that of proband En. The difference in lifespan probably reflects different postnatal treatment regimens rather than genetic heterogeneity. Unfortunately, studies on the quantity or biochemical properties of the OTC protein were not performed in either of these patients. Nevertheless (22) (23) (24) . The exon 26 example exactly parallels our OTC cases, with the difference that in Factor VIII, the missense substitution had a distinctly milder phenotype (23) . Thus, a number of factors are involved in determining whether a C:G to T:A transition mutation in the internal CG dinucleotide of a Taq I site will be phenotypically significant. One factor is whether the Taq I site resides in coding sequence. If so, its reading frame is another factor because if the Taq I site forms an arginine codon, such transition mutations will result in missense or nonsense mutations rather than silent substitutions. A third factor is the placement of the CGA codon in the coding region, since the effect of nonsense and missense mutations on protein function will depend on the position and role of the arginine residue.
There are three other Taq I sites in the OTC cDNA, all with the same reading frame. They are located at Arg.10, Arg6o, and Arg288 (15) . Judging from the published partial human and full rat genomic arrangements (25, 26) , all three exist intact in genomic DNA. If indeed they are subject to methylation, then point mutations at all three sites should appear among OTC deficiencies and be easily recognized by Taq I analysis. As a case in point, the Taq I site at Arg288 is implicated as the site of a new mutation in the mother of an additional OTC-deficient boy whose Southern blot (Spence, J. E., and W. E. O'Brien, manuscript in preparation) shows a Taq I fragment length change from 2.7 to 4.4 kb. Furthermore, at codons -10 and 60, in addition to the obvious impact of early stop codons, missense substitutions would appear to be very detrimental.
Arg-10 (Arg23 of the leader peptide) is critical for the mitochondrial targeting and proteolytic processing of the OTC precursor (27) , and Arg6o is conserved in all carbamyltransferases (reviewed in reference 21) and is thought to be part of the carbamyl phosphate binding site (28) . Naturally occurring mutations at the latter two sites have not yet been reported. OTC deficiency remains a heterogeneous entity caused by a variety of defects in the OTC gene, the majority of which are yet undefined. Each new mutation is potentially different; nevertheless, our cases Bo and En represent the first examples of independent recurrence of identical point mutations in this gene. As missense substitutions, they will also allow inferences to be drawn about the role of Arg109 in assembly and function of the mature enzyme. Together with the nonsense mutation of case Ma, they point to a codon in the OTC gene that is both susceptible to a common mutational mechanism and located in a sensitive position. Because this codon fortuitously contributes to a Taq I site in the normal gene, mutations like these are readily detectable by simple restriction analysis.
